

Margaret Okomo-Adhiambo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7379790/publications.pdf>

Version: 2024-02-01

26
papers

4,135
citations

361413

20
h-index

580821

25
g-index

27
all docs

27
docs citations

27
times ranked

3997
citing authors

#	ARTICLE	IF	CITATIONS
1	Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans. <i>Science</i> , 2009, 325, 197-201.	12.6	2,127
2	Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1034.	7.4	465
3	Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3284-3292.	3.2	441
4	Detection of Molecular Markers of Drug Resistance in 2009 Pandemic Influenza A (H1N1) Viruses by Pyrosequencing. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1102-1110.	3.2	116
5	Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infections, United States, 2010â€“11. <i>Emerging Infectious Diseases</i> , 2012, 18, 308-311.	4.3	89
6	Host cell selection of influenza neuraminidase variants: Implications for drug resistance monitoring in A(H1N1) viruses. <i>Antiviral Research</i> , 2010, 85, 381-388.	4.1	88
7	Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. <i>Antiviral Therapy</i> , 2010, 15, 1151-1159.	1.0	86
8	Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. <i>Antiviral Research</i> , 2009, 81, 16-24.	4.1	85
9	Detection of E119V and E119I Mutations in Influenza A (H3N2) Viruses Isolated from an Immunocompromised Patient: Challenges in Diagnosis of Oseltamivir Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1834-1841.	3.2	74
10	Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective. <i>Viruses</i> , 2010, 2, 2269-2289.	3.3	72
11	Characteristics of Patients with Oseltamivir-Resistant Pandemic (H1N1) 2009, United States. <i>Emerging Infectious Diseases</i> , 2011, 17, 255-257.	4.3	66
12	Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir. <i>Journal of Infectious Diseases</i> , 2015, 212, 1209-1213.	4.0	56
13	Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 645-658.	3.4	51
14	Oseltamivir-Resistant Influenza A(H1N1)pdm09 Viruses, United States, 2013â€“14. <i>Emerging Infectious Diseases</i> , 2015, 21, 136-141.	4.3	45
15	Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 44-49.	3.4	43
16	Cell Culture-Selected Substitutions in Influenza A(H3N2) Neuraminidase Affect Drug Susceptibility Assessment. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6141-6146.	3.2	41
17	cDNA Microarray Analysis of Host-Pathogen Interactions in a Porcine In Vitro Model for <i>Toxoplasma gondii</i> Infection. <i>Infection and Immunity</i> , 2006, 74, 4254-4265.	2.2	35
18	The Fluorescence Neuraminidase Inhibition Assay: A Functional Method for Detection of Influenza Virus Resistance to the Neuraminidase Inhibitors. <i>Methods in Molecular Biology</i> , 2012, 865, 115-125.	0.9	33

#	ARTICLE	IF	CITATIONS
19	Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011–2012: application of the WHO antiviral working group criteria. <i>Influenza and Other Respiratory Viruses</i> , 2014, 8, 258-265.	3.4	33
20	Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay. <i>Antiviral Research</i> , 2009, 82, 29-33.	4.1	27
21	Oseltamivir-Resistant Influenza A(H1N1)pdm09 Viruses, United States, 2013–14. <i>Emerging Infectious Diseases</i> , 2015, 21, 136-141.	4.3	20
22	The Chemiluminescent Neuraminidase Inhibition Assay: A Functional Method for Detection of Influenza Virus Resistance to the Neuraminidase Inhibitors. <i>Methods in Molecular Biology</i> , 2012, 865, 95-113.	0.9	13
23	Bioluminescence-Based Neuraminidase Inhibition Assay for Monitoring Influenza Virus Drug Susceptibility in Clinical Specimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5209-5215.	3.2	12
24	Application of a Seven-Target Pyrosequencing Assay To Improve the Detection of Neuraminidase Inhibitor-Resistant Influenza A(H3N2) Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2374-2379.	3.2	9
25	VPipe: an Automated Bioinformatics Platform for Assembly and Management of Viral Next-Generation Sequencing Data. <i>Microbiology Spectrum</i> , 2022, 10, e0256421.	3.0	8
26	Automated Next Generation Sequencing Bioinformatics Pipelines for Pathogen Discovery and Surveillance. , 2017, , .		0